| Robin K Rasmussen, MD | |
|
1100 Butte St, Redding, CA 96001-0852 | |
| (530) 244-5400 | |
| Not Available |
| Full Name | Robin K Rasmussen |
|---|---|
| Gender | Male |
| Speciality | Emergency Medicine |
| Experience | 28 Years |
| Location | 1100 Butte St, Redding, California |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1093828337 | NPI | - | NPPES |
| 00A669420 | Medicaid | CA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207P00000X | Emergency Medicine | A69942 (California) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Enloe Medical Center | Chico, CA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Enloe Medical Center | 9739092388 | 287 |
News Archive
Transient receptor potential channel A1 is one of the important transducers of noxious stimuli in the primary afferents, which may contribute to generation of neurogenic inflammation and hyperalgesia.
Three researchers from the Dermatology Research Foundation at the University of Sydney have identified a compound produced by certain fatal skin cancer tumours, providing new hope for developing treatments.
Agendia, a world leader in molecular cancer diagnostics, today announced that the company has received its fifth U.S. Food and Drug Administration clearance for MammaPrint, its widely used breast cancer recurrence assay.
As part of its expanding international program Hemispherx Biopharma, Inc., announced an agreement with Fountain Medical Development Ltd., a leading Chinese clinical research organization (CRO) to prepare, file and gain approval from the authorities in China to conduct a study of Ampligen, an investigational therapeutic.
› Verified 9 days ago
| Entity Name | Mayers Memorial Hospital District |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1912125667 PECOS PAC ID: 6305804196 Enrollment ID: O20041227000593 |
News Archive
Transient receptor potential channel A1 is one of the important transducers of noxious stimuli in the primary afferents, which may contribute to generation of neurogenic inflammation and hyperalgesia.
Three researchers from the Dermatology Research Foundation at the University of Sydney have identified a compound produced by certain fatal skin cancer tumours, providing new hope for developing treatments.
Agendia, a world leader in molecular cancer diagnostics, today announced that the company has received its fifth U.S. Food and Drug Administration clearance for MammaPrint, its widely used breast cancer recurrence assay.
As part of its expanding international program Hemispherx Biopharma, Inc., announced an agreement with Fountain Medical Development Ltd., a leading Chinese clinical research organization (CRO) to prepare, file and gain approval from the authorities in China to conduct a study of Ampligen, an investigational therapeutic.
› Verified 9 days ago
| Entity Name | Amador Emergency Physicians Medical Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1417040619 PECOS PAC ID: 2567495716 Enrollment ID: O20050916000969 |
News Archive
Transient receptor potential channel A1 is one of the important transducers of noxious stimuli in the primary afferents, which may contribute to generation of neurogenic inflammation and hyperalgesia.
Three researchers from the Dermatology Research Foundation at the University of Sydney have identified a compound produced by certain fatal skin cancer tumours, providing new hope for developing treatments.
Agendia, a world leader in molecular cancer diagnostics, today announced that the company has received its fifth U.S. Food and Drug Administration clearance for MammaPrint, its widely used breast cancer recurrence assay.
As part of its expanding international program Hemispherx Biopharma, Inc., announced an agreement with Fountain Medical Development Ltd., a leading Chinese clinical research organization (CRO) to prepare, file and gain approval from the authorities in China to conduct a study of Ampligen, an investigational therapeutic.
› Verified 9 days ago
| Entity Name | Enloe Medical Center |
|---|---|
| Entity Type | Part B Supplier - Hospital Department(s) |
| Entity Identifiers | NPI Number: 1164885604 PECOS PAC ID: 9739092388 Enrollment ID: O20160511001763 |
News Archive
Transient receptor potential channel A1 is one of the important transducers of noxious stimuli in the primary afferents, which may contribute to generation of neurogenic inflammation and hyperalgesia.
Three researchers from the Dermatology Research Foundation at the University of Sydney have identified a compound produced by certain fatal skin cancer tumours, providing new hope for developing treatments.
Agendia, a world leader in molecular cancer diagnostics, today announced that the company has received its fifth U.S. Food and Drug Administration clearance for MammaPrint, its widely used breast cancer recurrence assay.
As part of its expanding international program Hemispherx Biopharma, Inc., announced an agreement with Fountain Medical Development Ltd., a leading Chinese clinical research organization (CRO) to prepare, file and gain approval from the authorities in China to conduct a study of Ampligen, an investigational therapeutic.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Robin K Rasmussen, MD Po Box 11949, Westminster, CA 92685-1949 Ph: (866) 883-5374 | Robin K Rasmussen, MD 1100 Butte St, Redding, CA 96001-0852 Ph: (530) 244-5400 |
News Archive
Transient receptor potential channel A1 is one of the important transducers of noxious stimuli in the primary afferents, which may contribute to generation of neurogenic inflammation and hyperalgesia.
Three researchers from the Dermatology Research Foundation at the University of Sydney have identified a compound produced by certain fatal skin cancer tumours, providing new hope for developing treatments.
Agendia, a world leader in molecular cancer diagnostics, today announced that the company has received its fifth U.S. Food and Drug Administration clearance for MammaPrint, its widely used breast cancer recurrence assay.
As part of its expanding international program Hemispherx Biopharma, Inc., announced an agreement with Fountain Medical Development Ltd., a leading Chinese clinical research organization (CRO) to prepare, file and gain approval from the authorities in China to conduct a study of Ampligen, an investigational therapeutic.
› Verified 9 days ago
Jarred Anderson, DO Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 2175 Rosaline Ave, Redding, CA 96001 Phone: 530-225-6000 | |
Donald Gandy, DO Emergency Medicine Medicare: Medicare Enrolled Practice Location: 1100 Butte St, Redding, CA 96001 Phone: 530-243-0498 Fax: 530-243-1309 | |
Dr. Brett Ronald Ohlfs, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 1100 Butte St, Emergency Medicine Department, Redding, CA 96001 Phone: 530-244-5353 | |
Sheyann Kirby, DO Emergency Medicine Medicare: Medicare Enrolled Practice Location: 2175 Rosaline Ave, Redding, CA 96001 Phone: 530-225-6000 | |
Federico Grabiel, MD Emergency Medicine Medicare: Medicare Enrolled Practice Location: 2175 Rosaline Ave, Redding, CA 96001 Phone: 530-225-6000 Fax: 818-587-2493 | |
Dr. Ryan Meller, M.D. Emergency Medicine Medicare: Medicare Enrolled Practice Location: 2175 Rosaline Ave, Redding, CA 96001 Phone: 530-225-7240 Fax: 530-225-7249 |